A revolutionary medication , retatrutide, is sparking considerable anticipation within the Aussie weight control community. Designed by Lilly , this dual GIP and GLP-1 agonist appears to provide more impressive outcomes than existing therapies. Early medical trials have shown exceptional diminutions in overall fat , suggesting the potential for a n